Evaluation and Management of Vaginitis.
Marnach ML, Wygant JN, Casey PM.
Mayo Clin Proc. 2022 Feb;97(2):347-358. doi: 10.1016/j.mayocp.2021.09.022.
Vulvovaginal candidiasis and vaginal microflora interaction: Microflora changes and probiotic therapy.
Sun Z, Ge X, Qiu B, Xiang Z, Jiang C, Wu J, Li Y.
Front Cell Infect Microbiol. 2023 Feb 3;13:1123026. doi: 10.3389/fcimb.2023.1123026. eCollection 2023.
A probiotic nanozyme hydrogel regulates vaginal microenvironment for Candida vaginitis therapy.
Wei G, Liu Q, Wang X, Zhou Z, Zhao X, Zhou W, Liu W, Zhang Y, Liu S, Zhu C, Wei H.
Sci Adv. 2023 May 19;9(20):eadg0949. doi: 10.1126/sciadv.adg0949. Epub 2023 May 17.
Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review.
Kalia N, Singh J, Kaur M.
Ann Clin Microbiol Antimicrob. 2020 Jan 28;19(1):5. doi: 10.1186/s12941-020-0347-4.
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.
MacAlpine J, Lionakis MS.
Cell Host Microbe. 2024 Oct 9;32(10):1654-1667. doi: 10.1016/j.chom.2024.08.018.
Vaginitis.
Banner EA.
Med Clin North Am. 1974 Jul;58(4):759-68. doi: 10.1016/s0025-7125(16)32119-8.
Interpretation of vaginal metagenomic characteristics in different types of vaginitis.
Song J, Dong X, Lan Y, Lu Y, Liu X, Kang X, Huang Z, Yue B, Liu Y, Ma W, Zhang L, Yan H, He M, Fan Z, Guo T.
mSystems. 2024 Mar 19;9(3):e0137723. doi: 10.1128/msystems.01377-23. Epub 2024 Feb 16.
Candida vaginitis: virulence, host response and vaccine prospects.
De Bernardis F, Graziani S, Tirelli F, Antonopoulou S.
Med Mycol. 2018 Apr 1;56(suppl_1):26-31. doi: 10.1093/mmy/myx139.
Vaginal Candida albicans infections: host-pathogen-microbiome interactions.
Valentine M, Wilson D, Gresnigt MS, Hube B.
FEMS Microbiol Rev. 2025 Jan 14;49:fuaf013. doi: 10.1093/femsre/fuaf013.
Management of persistent vaginitis.
Nyirjesy P.
Obstet Gynecol. 2014 Dec;124(6):1135-1146. doi: 10.1097/AOG.0000000000000551.
